AITEM Trademark

Trademark Overview


On Friday, July 15, 2022, a trademark application was filed for AITEM with the United States Patent and Trademark Office. The USPTO has given the AITEM trademark a serial number of 79350047. The federal status of this trademark filing is REGISTERED as of Tuesday, April 30, 2024. This trademark is owned by BEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD. The AITEM trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Medicines for human purposes, namely, for use for central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney and gastrointestinal diseases; Pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Chemico-pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Capsules being medicines, namely, capsules for the treatment of central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney related diseases, gastrointestinal dise...

Design of computer databases; Conversion of computer programs and data, other than physical conversion; Digitization of documents being scanning; Computer programming in medical care; Providing virtual computer systems through cloud computing; Pharmaceutical drug development; Drug evaluation in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Pharmaceutical research; Scientific research and development; Conducting early evaluation of new drug fields in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Computer hardware design; Research and development of new products for others; Providing computer software design for others; Electronic data storage; Conducting technical project studies in the nature of technical research in the field of pharmaceutical studies; Conversion of data or documents from physical to electronic media; Clini...
aitem

General Information


Serial Number79350047
Word MarkAITEM
Filing DateFriday, July 15, 2022
Status700 - REGISTERED
Status DateTuesday, April 30, 2024
Registration Number7369448
Registration DateTuesday, April 30, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 13, 2024

Trademark Statements


Goods and ServicesMedicines for human purposes, namely, for use for central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney and gastrointestinal diseases; Pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Chemico-pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Capsules being medicines, namely, capsules for the treatment of central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney related diseases, gastrointestinal diseases; Sedatives; Vaccines; Drugs for medical purposes, namely, central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Medicines in tablet form, namely, medicinal preparations for the mouth to be applied in the form of tablets; Injectable medicinal solutions, namely, powder for injection, parenteral solutions, solutions for injection, intravenous injections, suspensions for injection, sterile powders for injection, intravenous injections, emulsion for injection, emulsion injections, powder injections, and concentrated solutions for injection, all for the treatment of central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney and gastrointestinal diseases; Pain relief medication; Immunostimulants; Pharmaceuticals for the treatment of cancer; Pharmaceuticals for the treatment of infectious diseases; Pharmaceuticals for the treatment of viral diseases; Medicinal preparations for the treatment of musculoskeletal disorders; Drugs and preparations for the treatment of gastrointestinal diseases; Medicinal preparations for skin diseases
Goods and ServicesDesign of computer databases; Conversion of computer programs and data, other than physical conversion; Digitization of documents being scanning; Computer programming in medical care; Providing virtual computer systems through cloud computing; Pharmaceutical drug development; Drug evaluation in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Pharmaceutical research; Scientific research and development; Conducting early evaluation of new drug fields in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Computer hardware design; Research and development of new products for others; Providing computer software design for others; Electronic data storage; Conducting technical project studies in the nature of technical research in the field of pharmaceutical studies; Conversion of data or documents from physical to electronic media; Clinical trials, namely, scientific research in the nature of conducting clinical trials for others; Animal genetics research in the nature of studying the mechanism of action of compound combinations in animals; Computer programming

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 20, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, September 20, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameHANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCN

Party NameBEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCN

Party NameHANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCN

Party NameBEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCN

Party NameHANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCN

Party NameBEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCN

Trademark Events


Event DateEvent Description
Friday, September 16, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, September 20, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 24, 2022APPLICATION FILING RECEIPT MAILED
Tuesday, May 2, 2023ASSIGNED TO EXAMINER
Wednesday, May 17, 2023NON-FINAL ACTION WRITTEN
Thursday, May 18, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, June 22, 2023REFUSAL PROCESSED BY MPU
Friday, June 23, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, July 22, 2023REFUSAL PROCESSED BY IB
Sunday, November 19, 2023ASSIGNED TO EXAMINER
Friday, December 8, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 8, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 8, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 4, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, January 4, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, January 4, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, January 4, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, January 10, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 24, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Monday, January 29, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, February 13, 2024PUBLISHED FOR OPPOSITION
Tuesday, February 13, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, February 19, 2024NOTIFICATION PROCESSED BY IB
Wednesday, February 21, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, February 26, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sunday, March 17, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, April 30, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 30, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 30, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, July 30, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, October 26, 2024GENERIC MADRID TRANSACTION CREATED
Sunday, October 27, 2024GENERIC MADRID TRANSACTION SENT TO IB
Saturday, December 7, 2024FINAL DECISION TRANSACTION PROCESSED BY IB